GlassScriptPhysician profile
Hammad Ur Rahman
NPI 1952754210
$5,337.64
in general payments reported to CMS, 2019-2025
13 companies · $4,884 in 2025
The $4,884 reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.67 · 2023: $149 · 2024: $215 · 2025: $4,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,579 · Food and Beverage: $1,668 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,579.40 |
| Food and Beverage | $1,667.57 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,664.86 | 2025 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $1,980.21 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $123.33 | 2025 | General - Vascular Access |
| Novartis Pharmaceuticals Corporation | $113.33 | 2022-2025 | |
| Pfizer INC. | $111.12 | 2022-2024 | |
| Amgen INC. | $85.93 | 2022-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.23 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $45.54 | 2023-2025 | Wegovy, Ozempic |
| Lexicon Pharmaceuticals, INC. | $36.63 | 2023-2024 | Inpefa |
| Abiomed | $34.91 | 2024 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $27.65 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $21.18 | 2023 | Amvuttra |
| Scpharmaceuticals INC. | $15.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.